Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.
Identifieur interne : 000539 ( PubMed/Corpus ); précédent : 000538; suivant : 000540Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.
Auteurs : Santiago Perez-Lloret ; Laurence Negre-Pages ; Philippe Damier ; Arnaud Delval ; Pascal Derkinderen ; Alain Destée ; Wassilios G. Meissner ; Ludwig Schelosky ; Francois Tison ; Olivier RascolSource :
- JAMA neurology [ 2168-6157 ] ; 2014.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Cross-Sectional Studies, Female, France (epidemiology), Gait (physiology), Humans, Levodopa (administration & dosage), Male, Muscarinic Antagonists (administration & dosage), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson Disease (physiopathology), Prevalence, Psychiatric Status Rating Scales, Quality of Life (psychology), Severity of Illness Index, Time Factors.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa, Muscarinic Antagonists.
- geographic , epidemiology : France.
- drug therapy : Parkinson Disease.
- epidemiology : Parkinson Disease.
- physiology : Gait.
- physiopathology : Parkinson Disease.
- psychology : Quality of Life.
- Aged, Cross-Sectional Studies, Female, Humans, Male, Prevalence, Psychiatric Status Rating Scales, Severity of Illness Index, Time Factors.
Abstract
Freezing of gait (FOG) is a common axial symptom of Parkinson disease (PD).
DOI: 10.1001/jamaneurol.2014.753
PubMed: 24839938
Links to Exploration step
pubmed:24839938Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation><nlm:affiliation>Department of Clinical Pharmacology, Faculty of Medicine, University Hospital, University of Toulouse, Toulouse, France2Department of Neurosciences, University Hospital, University of Toulouse, Toulouse, France3Clinical Investigation Center 1436, Universi.</nlm:affiliation></affiliation></author><author><name sortKey="Negre Pages, Laurence" sort="Negre Pages, Laurence" uniqKey="Negre Pages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name><affiliation><nlm:affiliation>LN Pharma, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name><affiliation><nlm:affiliation>Department of Neurology, Hôpital Laënnec, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France6NS-Park Network, INSERM, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Delval, Arnaud" sort="Delval, Arnaud" uniqKey="Delval A" first="Arnaud" last="Delval">Arnaud Delval</name><affiliation><nlm:affiliation>Department of Neurology, CHU Lille, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Derkinderen, Pascal" sort="Derkinderen, Pascal" uniqKey="Derkinderen P" first="Pascal" last="Derkinderen">Pascal Derkinderen</name><affiliation><nlm:affiliation>Department of Neurology, Hôpital Laënnec, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France6NS-Park Network, INSERM, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name><affiliation><nlm:affiliation>NS-Park Network, INSERM, Toulouse, France7Department of Neurology, CHU Lille, Lille, France8INSERM U 837 Eq6, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Meissner, Wassilios G" sort="Meissner, Wassilios G" uniqKey="Meissner W" first="Wassilios G" last="Meissner">Wassilios G. Meissner</name><affiliation><nlm:affiliation>Institut des Maladies Neurodégénératives, Université de Bordeaux, Bordeaux, France10Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, France11Service de Neurologie, CHU de Bordeaux, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name><affiliation><nlm:affiliation>Neurology Department, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="Francois" last="Tison">Francois Tison</name><affiliation><nlm:affiliation>NS-Park Network, INSERM, Toulouse, France9Institut des Maladies Neurodégénératives, Université de Bordeaux, Bordeaux, France10Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, France11Service de Neurologie.</nlm:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><nlm:affiliation>Department of Clinical Pharmacology, Faculty of Medicine, University Hospital, University of Toulouse, Toulouse, France2Department of Neurosciences, University Hospital, University of Toulouse, Toulouse, France3Clinical Investigation Center 1436, Universi.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24839938</idno><idno type="pmid">24839938</idno><idno type="doi">10.1001/jamaneurol.2014.753</idno><idno type="wicri:Area/PubMed/Corpus">000539</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000539</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation><nlm:affiliation>Department of Clinical Pharmacology, Faculty of Medicine, University Hospital, University of Toulouse, Toulouse, France2Department of Neurosciences, University Hospital, University of Toulouse, Toulouse, France3Clinical Investigation Center 1436, Universi.</nlm:affiliation></affiliation></author><author><name sortKey="Negre Pages, Laurence" sort="Negre Pages, Laurence" uniqKey="Negre Pages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name><affiliation><nlm:affiliation>LN Pharma, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name><affiliation><nlm:affiliation>Department of Neurology, Hôpital Laënnec, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France6NS-Park Network, INSERM, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Delval, Arnaud" sort="Delval, Arnaud" uniqKey="Delval A" first="Arnaud" last="Delval">Arnaud Delval</name><affiliation><nlm:affiliation>Department of Neurology, CHU Lille, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Derkinderen, Pascal" sort="Derkinderen, Pascal" uniqKey="Derkinderen P" first="Pascal" last="Derkinderen">Pascal Derkinderen</name><affiliation><nlm:affiliation>Department of Neurology, Hôpital Laënnec, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France6NS-Park Network, INSERM, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name><affiliation><nlm:affiliation>NS-Park Network, INSERM, Toulouse, France7Department of Neurology, CHU Lille, Lille, France8INSERM U 837 Eq6, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Meissner, Wassilios G" sort="Meissner, Wassilios G" uniqKey="Meissner W" first="Wassilios G" last="Meissner">Wassilios G. Meissner</name><affiliation><nlm:affiliation>Institut des Maladies Neurodégénératives, Université de Bordeaux, Bordeaux, France10Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, France11Service de Neurologie, CHU de Bordeaux, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name><affiliation><nlm:affiliation>Neurology Department, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="Francois" last="Tison">Francois Tison</name><affiliation><nlm:affiliation>NS-Park Network, INSERM, Toulouse, France9Institut des Maladies Neurodégénératives, Université de Bordeaux, Bordeaux, France10Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, France11Service de Neurologie.</nlm:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><nlm:affiliation>Department of Clinical Pharmacology, Faculty of Medicine, University Hospital, University of Toulouse, Toulouse, France2Department of Neurosciences, University Hospital, University of Toulouse, Toulouse, France3Clinical Investigation Center 1436, Universi.</nlm:affiliation></affiliation></author></analytic><series><title level="j">JAMA neurology</title><idno type="eISSN">2168-6157</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Cross-Sectional Studies</term><term>Female</term><term>France (epidemiology)</term><term>Gait (physiology)</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Male</term><term>Muscarinic Antagonists (administration & dosage)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (physiopathology)</term><term>Prevalence</term><term>Psychiatric Status Rating Scales</term><term>Quality of Life (psychology)</term><term>Severity of Illness Index</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term><term>Muscarinic Antagonists</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Gait</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Quality of Life</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Prevalence</term><term>Psychiatric Status Rating Scales</term><term>Severity of Illness Index</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Freezing of gait (FOG) is a common axial symptom of Parkinson disease (PD).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24839938</PMID><DateCreated><Year>2014</Year><Month>07</Month><Day>15</Day></DateCreated><DateCompleted><Year>2014</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.</ArticleTitle><Pagination><MedlinePgn>884-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.753</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Freezing of gait (FOG) is a common axial symptom of Parkinson disease (PD).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the prevalence of FOG in a large group of PD patients, assess its relationship with quality of life and clinical and pharmacological factors, and explore its changes from the off to on conditions in patients with motor fluctuations.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Cross-sectional survey of 683 patients with idiopathic PD. Scores for FOG were missing in 11 patients who were not included in the analysis. Patients were recruited from referral centers and general neurology clinics in public or private institutions in France.</AbstractText><AbstractText Label="EXPOSURE" NlmCategory="METHODS">Patients with FOG were identified as those with a score of 1 or greater on item 14 of the Unified Parkinson's Disease Rating Scale (UPDRS) in the on condition. Item 14 scores for FOG in the off condition were also collected in patients with fluctuating motor symptoms.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Quality of life (measured by the 39-item Parkinson's Disease Questionnaire and 36-Item Short Form Health Survey), anxiety and depression (Hospital Anxiety and Depression Scale), clinical features (UPDRS), and drug consumption.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 672 PD patients, 257 reported FOG during the onstate (38.2%), which was significantly related to lower quality of life scores (P < .01). Freezing of gait was also correlated with longer PD duration (odds ratio, 1.92 [95% CI, 1.28-2.86]), higher UPDRS parts II and III scores (4.67 [3.21-6.78]), the presence of apathy (UPDRS item 4) (1.94 [1.33-2.82]), a higher levodopa equivalent daily dose (1.63 [1.09-2.43]), and more frequent exposure to antimuscarinics (3.07 [1.35-6.97]) (logistic regression). The FOG score improved from the off to on states in 148 of 174 patients with motor fluctuations (85.1%) and showed no change in 13.8%. The FOG score improved by more than 50% in 43.7% of patients. Greater improvement in the on state was observed in younger patients (r = -0.25; P < .01) with lower UPDRS II and III scores (r = -0.50; P < .01) and no antimuscarinic use (r = -0.21; P < .01).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Freezing of gait in PD patients correlates with poor quality of life, disease severity, apathy, and exposure to antimuscarinics. Dopaminergic therapy improved FOG in most patients with motor fluctuations, especially younger ones with less severe disease and no antimuscarinic use. This finding suggests that quality of life is impaired in PD patients with FOG and that optimizing dopaminergic therapy and avoiding antimuscarinics should be considered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perez-Lloret</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Faculty of Medicine, University Hospital, University of Toulouse, Toulouse, France2Department of Neurosciences, University Hospital, University of Toulouse, Toulouse, France3Clinical Investigation Center 1436, Universi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negre-Pages</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>LN Pharma, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hôpital Laënnec, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France6NS-Park Network, INSERM, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delval</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derkinderen</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hôpital Laënnec, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France6NS-Park Network, INSERM, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Destée</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NS-Park Network, INSERM, Toulouse, France7Department of Neurology, CHU Lille, Lille, France8INSERM U 837 Eq6, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meissner</LastName><ForeName>Wassilios G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Institut des Maladies Neurodégénératives, Université de Bordeaux, Bordeaux, France10Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, France11Service de Neurologie, CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schelosky</LastName><ForeName>Ludwig</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurology Department, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tison</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NS-Park Network, INSERM, Toulouse, France9Institut des Maladies Neurodégénératives, Université de Bordeaux, Bordeaux, France10Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, France11Service de Neurologie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Faculty of Medicine, University Hospital, University of Toulouse, Toulouse, France2Department of Neurosciences, University Hospital, University of Toulouse, Toulouse, France3Clinical Investigation Center 1436, Universi.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005684" MajorTopicYN="N">Gait</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="N">Muscarinic Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24839938</ArticleId><ArticleId IdType="pii">1871698</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.753</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000539 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000539 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24839938
|texte= Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24839938" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |